Skip to main content
TipRanks
Go Ultimate75% OFF

Madrigal Pharmaceuticals (YDO1) Stock Price & Analysis

0 Followers

YDO1 Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 7.75B
Enterprise Value
CHF 14.67B
Total Cash (Recent Filing)
CHF 960.97M
Total Debt (Recent Filing)
CHF 354.22M
Price to Earnings (P/E)
―
Beta
N/A
Next Earnings
Feb 25, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Rapid Rezdiffra Revenue Growth

Rapid sales growth indicates strong commercial adoption of Rezdiffra and expanding execution in the MASH market. If sustained, the larger revenue base can support operating leverage, broaden the company’s strategic options, and fund continued investment in clinical development.

Large Market Runway

Low current penetration alongside expected double-digit market growth provides a substantial runway for continued product expansion. This supports a durable growth opportunity beyond the initial launch phase, provided Madrigal maintains access, prescriber engagement, and patient adoption.

Improving Profitability And Cash Generation

The first profitable quarter and two consecutive quarters of positive operating cash flow mark an important commercialization inflection. Sustaining this progress could reduce dependence on external financing, strengthen balance-sheet flexibility, and support pipeline investment from internally generated resources.

Bears Say

TTM Losses And Negative Free Cash Flow

Despite sharply narrowing losses, the trailing period remains unprofitable and consumes cash. Continued negative free cash flow would limit self-funding capacity and leave execution dependent on maintaining liquidity while management works to convert commercialization growth into consistent earnings.

High Commercial Cost Burden

Heavy commercial investment and substantial gross-to-net deductions can constrain the conversion of strong prescription growth into durable operating profit. Rising selling expenses and rebates may require sustained revenue expansion and disciplined cost control before margins become consistently attractive.

Long, Event-dependent Pipeline Timelines

Expansion into additional MASH populations depends on clinical programs with long and event-driven timelines. Delayed readouts defer potential indications and reduce near-term pipeline contribution, leaving the company more reliant on Rezdiffra’s current market execution for several years.

Madrigal Pharmaceuticals News

YDO1 FAQ

What is Madrigal Pharmaceuticals’s market cap?
Madrigal Pharmaceuticals’s market cap is CHF7.75B.
When is Madrigal Pharmaceuticals’s upcoming earnings report date?
Madrigal Pharmaceuticals’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 96 days.
How were Madrigal Pharmaceuticals’s earnings last quarter?
Madrigal Pharmaceuticals released its earnings results on Nov 03, 2026. The company reported CHF1.523 earnings per share for the quarter, beating the consensus estimate of -CHF0.718 by CHF2.241.
Is Madrigal Pharmaceuticals overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Madrigal Pharmaceuticals pay dividends?
Madrigal Pharmaceuticals does not currently pay dividends.
What is Madrigal Pharmaceuticals’s EPS estimate?
Madrigal Pharmaceuticals’s EPS estimate is 1.19.
What happened to Madrigal Pharmaceuticals’s price movement after its last earnings report?
Madrigal Pharmaceuticals reported an EPS of CHF1.523 in its last earnings report, beating expectations of -CHF0.718. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals?
Hedge funds hold Madrigal Pharmaceuticals shares: the largest hedge-fund position in Madrigal Pharmaceuticals is 1,833,731,164 shares, and hedge funds decreased their holdings by 89.6K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology